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Acromegaly is a slowly progressive disease caused by excessive growth hormone (GH), which is related to a GH secreting pitu-
itary tumor in most cases. Herein, we describe the epidemiology, clinical characteristics, and treatment of acromegaly in Korea 
with a literature review. The average annual incidence of acromegaly in Korea was 3.9 cases per million people, which was with-
in the range of previous Western studies. The primary treatment for acromegaly was also transsphenoidal adenomectomy, which 
accounted for 90.4% of patients whose primary therapeutic options were known. The overall surgical remission rates were 89%, 
87%, 64%, 70%, and 50% for modified Hardy classification I, II, IIIA, IIIB, and IV, respectively. An updated and larger study re-
garding the treatment outcome of medical/radiotherapy in Korean acromegalic patients is needed.
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INTRODUCTION
Acromegaly is a slow progressing disease caused by excessive 
growth hormone (GH), which is related to a GH secreting pi-
tuitary tumor in most cases. Patients with acromegaly general-
ly exhibit acral enlargement, increased skin thickness, and fa-
cial bony deformities, including prognathism, nasal bone hy-
pertrophy, and frontal bossing. More importantly, an approxi-
mate 30% mortality rate increase has been reported in patients 
with acromegaly. Particularly, cardiovascular disease represents 
the cause of death in 60%, respiratory disease in 25%, and ma-
lignancies in 15% of overall mortalities [1]. Recent meta-analy-
sis showed approximately a 72% increase in all cause mortali-
ty in patients with acromegaly, compared with the general pop-
ulation, even after transsphenoidal adenomectomy (TSA) [2]. 
Therefore, early diagnosis and treatment to improve long-term 
morbidity and mortality, as well as relieve symptoms, are im-
portant.
 Unfortunately, a clinical review of acromegaly data in Ko-
rea has not yet been performed. Herein, we described the epi-
demiology, clinical characteristics, and treatment of acromeg-
aly in Korea with literature review.
EPIDEMIOLOGY IN KOREA
The prevalence of acromegaly has been estimated to be 40 to 
70 cases per million with three to four cases per million of the 
annual incidence in Western countries [3]. However, recent 
studies have reported that the prevalence of acromegaly could 
be much higher, including 122 cases per million in a Belgium 
study [4] and 1,034 cases per million in a German study [5].
 In Korea, the first nationwide survey regarding clinical char-
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acteristics of acromegaly was performed in 1994 [6]. Yang et 
al. [6] reported that 279 patients were newly diagnosed during 
the period from 1988 to 1992 with a rate of 1.4 cases per mil-
lion, which is much lower than the estimated annual incidence 
of Western countries. However, patient and primary physician 
awareness, as well as improvement in medical care due to eco-
nomic growth have increased the diagnostics rate of acromeg-
aly. With this background, an updated version of a nationwide 
survey regarding acromegalic patients in Korea has been re-
cently published. Kwon et al. [7] obtained all possible medical 
records of acromegalic patients collected by 74 secondary or 
tertiary medical institutes from 2003 to 2007. He reported that 
the prevalence of acromegaly was 27.9 cases per million in 
2007 (Fig. 1). The average annual incidence of acromegaly was 
3.9 cases per million, which was within the range of previous 
Western studies [7].
CLINICAL MANIFESTATIONS OF 
ACROMEGALY
The clinical manifestations of acromegaly are due to either to 
the consequences of GH hypersecretion or the tumor mass it-
self. GH hypersecretion leads to excessive growth, resulting in 
the classical features and medical comorbidities of acromega-
ly. The tumor mass effects can lead to headache, visual loss, 
and hypopituitarism. Unfortunately, there have been no reports 
on the clinical features of Korean acromegalic patients.
 The typical features include signs of somatic overgrowth, 
including soft tissue swelling, enlarged hands and feet, arthral-
gias, and prognathism [8]. However, only a fraction of patients 
with acromegaly are actually diagnosed following presentation 
with a chief complaint attributable to acral overgrowth. In a 
review of 164 patients with acromegaly, only 58 (35%) pre-
sented because of a change in features [9]. In this study, 56 pa-
tients (34%) presented because of disturbances associated with 
acromegaly, including visual field defects, carpal tunnel syn-
drome, and headaches. The remaining 50 individuals had no 
complaints related directly to acromegaly, and were diagnosed 
when seeking medical attention for unrelated complaints. These 
data demonstrate the difficulties in detecting the disease, as it 
is relatively uncommon that patients present with complaints 
attributable to the more classical signs of acromegaly, includ-
ing bony or soft tissue overgrowth. In addition, because the 
features of acromegaly progress in an insidious fashion, there 
is often a 7 to 10 year diagnosis delay after the estimated onset 
of symptoms [10].
 Besides the mass effect, chronic GH and insulin-like growth 
factor 1 (IGF-1) hypersecretion can lead to a myriad of soft tis-
sue and bone overgrowth manifestations, medical comorbidi-
ties, and accompanying clinical features. They include stimu-
lation of growth of many tissues, such as skin, connective tis-
sue, cartilage, bone, viscera, and epithelial tissues. Concerning 
the mortality of acromegaly, many studies have been focused 
on the development of cardiovascular disease and neoplasms.
 Hypertension is detected in up to 40% of individuals, and is 
presumably secondary to an increase in plasma volume along 
with an increase in sodium retention [11]. Suppressed plasma 
rennin activity and aldosterone concentrations in acromegaly 
are consistent with a primary increase in total body sodium. The 
presence of insulin resistance, a hyperdynamic cardiomyopa-
thy with increased cardiac output, as well as morphological al-
terations and/or endothelial dysfunction may also contribute to 
the hypertension [12]. Cardiovascular abnormalities include 
hypertension, left ventricular hypertrophy, and cardiomyopa-
thy. Interestingly, acromegaly may be associated with an in-
crease in carotid artery intima-media thickness, though the 
prevalence of atherosclerosis may be similar to that of the gen-
eral population. This finding suggests that GH and/or IGF-1 
may limit the progression of atherosclerosis, despite the coex-
istence of hypertension and glucose intolerance. An acrome-
galic cardiomyopathy, characterized by biventricular cardiac 
hypertrophy, is a hallmark finding in patients with acromegaly. 
Both age and disease duration correlate with the presence and 
degree of the hypertrophy [13]. The cardiomyopathy may prog-
ress with signs of diastolic dysfunction and/or insufficient sys-
tolic performance early in the disease process, to systolic dys-
Fig. 1. Prevalence and incidence of acromegaly in South Korea. 
Adapted from Kwon et al. Clin Endocrinol (Oxf) 2013;78:577-85, 
with permission from Blackwell Publishing [7].
c.p.m., cases per million.
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function at rest, and, rarely with advanced disease, overt heart 
failure [14]. Cardiac valve dysfunction may be detected in ac-
romegaly patients; arrhythmias, including atrial fibrillation, 
supraventricular tachycardia, and bundle branch blocks, may 
be detected as well [15].
 An increased risk of cancer, particularly colonic, with acro-
megaly has been suggested largely by retrospective studies, 
though this finding is controversial [8,16]. In one study, the 
overall cancer mortality rate was not increased, but the colon 
cancer mortality rate (standardized mortality ratio, 2.47) was 
higher than expected for the general population [17]. In addi-
tion, many, but not all, studies have reported that colonic pol-
yps are more prevalent in acromegalic patients than controls 
[18]. These findings are highly suggestive of a connection be-
tween GH hypersecretion and neoplasm growth, particularly 
of the colon.
TREATMENT OUTCOME OF 
ACROMEGALY IN KOREA
The treatment of acromegaly focuses on normalization of GH/
IGF-1 secretion, which is the most important factor required 
for reversing the observed increased morbidity and mortality. 
TSA is generally the first line treatment for acromegaly. When 
surgery fails to achieve control of GH/IGF-1 hypersecretion, 
medical treatment with a somatostatin analogue is preferred to 
radiotherapy.
 Although surgery is the most rapid way of reducing tumor 
volume and GH/IGF-1, the overall surgical cure rate has been 
reported only as 40% to 70%, depending on the size of the tu-
mor (microadenoma, 70% to 90%; macroadenoma, less than 
50%), preoperative GH concentrations, and the surgeon’s ex-
perience [19-21].
 In Korea, according to the report by Kwon et al. [7], among 
1,137 patients whose primary therapeutic options were known, 
TSA was also the primary treatment in 1,028 patients (90.4%). 
The remission rate at 3 months after TSA was 62.8% and 44.1% 
for microadenoma and macroadenoma, respectively. Among 
344 patients who were not in remission three months after TSA 
from 2003 to 2007 and whose medical treatment histories were 
collected, 157 patients (45.6%) received medical treatment in-
cluding somatostatin analogue or dopamine agonist.
 A retrospective study of 282 patients with GH-secreting pi-
tuitary tumors who underwent TSA by a single experienced 
neurosurgeon (S.H.K.) over a 17-year period was recently pub-
lished [22]. The study showed the overall surgical remission 
rates were 89%, 87%, 64%, 70%, and 50% for modified Har-
dy classifications I, II, IIIA, IIIB, and IV, respectively (Table 1). 
Ku et al. [22] also suggested that extensive surgical resection 
could achieve higher remission rates and lower recurrence rates 
without aggravating postoperative hypopituitarism.
 Medical therapy for acromegaly is usually indicated after 
unsuccessful TSA and while awaiting the effect of radiothera-
py [1]. Dopamine agonists and somatostatin analogues are 
available in Korea. Bromocriptine has been traditionally used 
in the past to treat acromegaly. However, cabergoline has been 
shown to be more effective and have less side effects than bro-
mocriptine. A meta-analysis showed cabergoline monotherapy 
can normalize IGF-1 levels in one third of acromegalic patients. 
When a somatostatin analog fails to control acromegaly, cab-
ergoline cotreatment was shown to normalize IGF-1 in about 
50% cases, even in patients with normoprolactinemia [23]. 
Somatostatin analogues, including octreotide and lanreotide, 
suppress GH secretion by binding to somatostatin receptors, 
SST2 and 5. These drugs normalize IGF-1 levels in 50% to 
80% patients and reduce the tumor volume in 20% to 70% of 
patients [21]. Unfortunately, there has been no data generated 
Table 1. Clinical Characteristics according to Surgical Out-
come in Patients with Acromegaly
Characteristic Total  (n=282)
Remission
Yes (n=210) No (n=72)
Mean agea 41.8±11.1 42.9±11.1 38.5±10.3 
Sex
Male 121 97 (80.2) 24 (19.8)
Female 161 113 (70.2) 48 (29.8)
Preoperation IGF-1 720.3±260.0 732.1±271.9 671.6±199.7
Hardy classificationb
I 75 67 (89.3) 8 (10.7)
II 55 48 (87.3) 7 (12.7)
IIIA 22 14 (63.6) 8 (36.4)
IIIB 82 57 (69.5) 25 (30.5)
IV 48 24 (50.0) 24 (50.0)
Values are expressed as mean±SD or number (%). Adapted from Ku et 
al. Neurosurgery 2012;71(2 Suppl Operative):ons192-203, with per-
mission from Wolters Kluwer Health [22].
IGF-1, insulin-like growth factor 1.
aP=0.003, independent-sample t test (odds ratio [OR], 1.038; 95% 
confidence interval [CI], 1.012 to 1.065; P=0.004); bP<0.001, Pearson 
chi-square (OR, 0.209; 95% CI, 0.067 to 0.651; P=0.007), (OR, 0.272; 
95% CI, 0.114 to 0.651; P=0.003), and (OR, 0.119; 95% CI, 0.047 to 
0.302; P<0.001), Hardy classification I vs. IIIA, IIIB, and IV, respec-
tively; remitted patients vs. nonremitted patients.
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regarding the outcome of medical treatment in Korean acro-
megalic patients.
 Radiotherapy can reduce tumor volume and GH/IGF-1 hy-
persecretion, but the onset of action is delayed and hypopituita-
rism usually develops [21]. External beam radiotherapy (EBRT) 
normalized IGF-1 level in about 36% of patients [24]. Stereotac-
tic radiosurgery allows the administration of a very large radia-
tion dose to an extremely defined area and induces a decrease 
in GH/IGF-1 levels more effectively and faster than conven-
tional EBRT. Approximately 58% of patients treated with ste-
reotactic radiosurgery achieved normalization of GH/IGF-1 
level [25]. However, the role of radiotherapy has become more 
and more controversial due to the improvement of surgical tech-
niques and availability of newer, more effective drugs [1,24].
 In Korea, the local control rate of radiotherapy including 
EBRT and stereotactic radiosurgery of pituitary tumor were as 
reported 66% and 92%, respectively, in recent data. However, 
the numbers of acromegaly patients enrolled in those studies 
were very small (n=9 and n=6) [26,27].
 An updated and larger study regarding the medical/radiother-
apy treatment outcome of acromegaly is needed.
CONCLUSIONS
The average annual incidence of acromegaly in Korea was 3.9 
cases per million, which was within the range of previous West-
ern studies. The primary treatment of acromegaly was also 
TSA, which accounts for 90.4% of patients whose primary ther-
apeutic options were known. Overall surgical remission rates 
were above 85% in intrasellar adenoma, however, only 50% to 
70% in extrasellar adenoma. An updated and larger study re-
garding the medical/radiotherapy treatment outcome in Kore-
an acromegalic patients is needed.
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